Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

CureVac Yönetim

Yönetim kriter kontrolleri 2/4

CureVac's CEO'su Alexander Zehnder, Apr2023 tarihinde atandı, in görev süresi 1.5 yıldır. in toplam yıllık tazminatı € 978.33K olup, şirket hissesi ve opsiyonları dahil olmak üzere 51.1% maaş ve 48.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.025% ine doğrudan sahiptir ve bu hisseler $ 165.73K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 8.6 yıldır.

Anahtar bilgiler

Alexander Zehnder

İcra Kurulu Başkanı

€978.3k

Toplam tazminat

CEO maaş yüzdesi	51.1%
CEO görev süresi	1.5yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	8.6yrs

Son yönetim güncellemeleri

Recent updates

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

Jul 05

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

Jul 04

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02

CEO Tazminat Analizi

Alexander Zehnder'un ücretlendirmesi CureVac'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€278m
Mar 31 2024	n/a	n/a	-€273m
Dec 31 2023	€978k	€500k	-€260m

Tazminat ve Piyasa: Alexander 'nin toplam tazminatı ($USD 1.08M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.23M ).

Tazminat ve Kazançlar: Alexander şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Alexander Zehnder (54 yo)

1.5yrs

Görev süresi

€978,331

Tazminat

Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alexander Zehnder	CEO, MD & Member of Management Board	1.5yrs	€978.33k	0.025% € 170.2k
Pierre Kemula	MD, CFO & Member of Management Board	8yrs	€654.18k	0.035% € 238.6k
Malte Greune	COO, Member of Management Board & MD	3.3yrs	€600.74k	0.0038% € 25.7k
Myriam Mendila	Chief Scientific Officer	1.8yrs	€614.49k	0.0021% € 14.4k
Ulrike Gnad-Vogt	Senior VP & Area Head of Oncology	1.8yrs	€284.15k	Veri yok
Sarah Fakih	Vice President Corporate Communications & Investor Relations	no data	Veri yok	Veri yok
Marco Rau	General Counsel	no data	Veri yok	Veri yok
Thorsten Schuller	Head of Corporate Communications	no data	Veri yok	Veri yok
Slavica Stevanovic-Heck	Head of Human Resources	no data	Veri yok	Veri yok
Patrick Baumhof	Senior Vice President of Technology	no data	Veri yok	Veri yok
Ronald Plasterk	Senior Vice President of Science & Innovation	no data	Veri yok	Veri yok
Marcus Dalton	Head of Intellectual Property	no data	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: CVAC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hans-Georg Rammensee	Scientific Director of Immunology and Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Craig Tooman	Supervisory Board Member	5.3yrs	€96.25k	0.0043% € 29.1k
Karim Fizazi	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Michael Brosnan	Independent Director of Supervisory Board	1.3yrs	€51.03k	0.0019% € 12.7k
Baron Stephenne	Independent Chairman of Supervisory Board	9.2yrs	€123.75k	0.0075% € 50.6k
Nina Bhardwaj	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Stanley Plotkin	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Michael Manns	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Jean-Paul Prieels	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Mathias Hothum	Supervisory Board Member	9.2yrs	€96.25k	0.0048% € 32.7k
Dirk Jäger	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Christopher Karp	Member of Scientific Advisory Board	8.6yrs	Veri yok	Veri yok

8.6yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CVAC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.6 yıldır).

CureVac Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CureVac N.V. Announces Pierre Kemula, Chief Financial Officer, to Step Down At the End of His Term October 31, 2024

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. Announces Executive Changes

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

Recent updates

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V. to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac N.V. Announces Pierre Kemula, Chief Financial Officer, to Step Down At the End of His Term October 31, 2024

CureVac N.V. to Report Q2, 2024 Results on Aug 15, 2024

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 29%, EPS upgraded

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Consensus revenue estimates increase by 57%

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Consensus revenue estimates decrease by 42%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

Now 31% undervalued

CureVac N.V. Announces CEO Changes

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CureVac Announces Executive Changes

CureVac BV reports Q2 results

Consensus estimates of losses per share improve by 10%

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Insider notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 36%

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV